Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences (PLSE) will feature its nPulse technology at the International Ventricular Arrhythmias Symposium in New York on October 9–10, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Preclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21^st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York.

A presentation at the Symposium will feature preclinical applications of two nPulse prototype endocardial catheters designed to demonstrate the potential for treatment of ventricular arrhythmias.

Presentation | Pulse Field Ablation of Ventricular Arrhythmias – Part II
Date: Saturday, October 10, 2026
Time: 5:20 p.m. – 5:30 p.m.
Location: New York Marriott at the Brooklyn Bridge – Room X

• Presentation: Recent Advances in PFA of Ventricular Arrhythmias
• Presenter: Jacob Koruth, MD

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including statements concerning the potential of the Company’s nsPFA technology to treat ventricular arrhythmias or any other ventricular disease. Results observed in preclinical studies are not necessarily predictive of results in human clinical studies, and there can be no assurance that Pulse Biosciences will initiate a human clinical study or a development program for any ventricular indication, or successfully develop any product for such use. You should not place undue reliance on forward-looking statements, which involve risks and uncertainties that are difficult to predict. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008662759/en/

Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com

Or

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

Key Terms

pulsed field ablation medical

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

endocardial catheters medical

Catheters designed to be placed inside the heart chambers so their tips sit on or near the endocardium (the heart’s inner lining) to diagnose or treat cardiac conditions. They are inserted through blood vessels and guided into the heart to record electrical signals, pace the heart, deliver energy for ablation, deliver drugs, or measure pressures; some have electrodes, sensors, or energy-delivery elements built into the shaft or tip. Because they operate inside the heart, their design and use focus on precise placement, compatibility with imaging and mapping systems, and single-use or sterilization requirements under medical-device regulations; they are distinct from epicardial devices that work on the outer heart surface.

ventricular arrhythmias medical

Ventricular arrhythmias are abnormal electrical rhythms that start in the heart’s lower chambers (ventricles), ranging from occasional extra beats to fast, chaotic patterns that can stop the heart from pumping effectively. Think of the heart as a metronome-driven pump: when the timing in the lower chambers goes wrong, blood flow can drop or stop. For investors, these events matter because they strongly influence the safety profile, regulatory review, trial outcomes, liability risk, and market value of drugs, devices, and healthcare companies involved in cardiovascular treatments.